Ryzneuta
Product Description
Menagen Pharmaceuticals
-
OM -
2024On CPHI since
-
1Certificates
-
100 - 249Employees
Company types
Categories
Specifications
Menagen Pharmaceuticals
-
OM
-
2024On CPHI since
-
1Certificates
-
100 - 249Employees
Company types
More Products from Menagen Pharmaceuticals (4)
-
Product Darbegen
Indicated for Chronic Kidney Disease Anemia -
Product Ezirosy
Treatment for Dyslipidemia -
Product Nitisinone Menagen
Indicated for hereditary tyrosinemia type 1 -
Product Renagen
Indicated for hyperphosphatemia
Menagen Pharmaceuticals resources (2)
-
News taiba Make Strategic Investment in Immuneel Therapeutics to advance CAR T-cell Research and Make Therapies More Affordable
taiba has announced a strategic investment in Immuneel Therapeutics for $12 million. -
News Menagen and Pharmosa Announce In-Licensing Collaboration for Sustained-Release Inhaled Treprostinil Product in MENAT Region
Menagen exclusively licenses MENAT rights for inhaled formulation of treprostinil
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance